These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26166735)

  • 1. Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
    Baer R; Cintas C; Therville N; Guillermet-Guibert J
    Adv Biol Regul; 2015 Sep; 59():19-35. PubMed ID: 26166735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer.
    Stoll V; Calleja V; Vassaux G; Downward J; Lemoine NR
    Gut; 2005 Jan; 54(1):109-16. PubMed ID: 15591514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review).
    Toren P; Zoubeidi A
    Int J Oncol; 2014 Nov; 45(5):1793-801. PubMed ID: 25120209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling.
    Arcaro A; Aubert M; Espinosa del Hierro ME; Khanzada UK; Angelidou S; Tetley TD; Bittermann AG; Frame MC; Seckl MJ
    Cell Signal; 2007 May; 19(5):1081-92. PubMed ID: 17275257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/AKT signaling pathway and cancer: an updated review.
    Martini M; De Santis MC; Braccini L; Gulluni F; Hirsch E
    Ann Med; 2014 Sep; 46(6):372-83. PubMed ID: 24897931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLC and PI3K/Akt/mTOR signalling in disease and cancer.
    Follo MY; Manzoli L; Poli A; McCubrey JA; Cocco L
    Adv Biol Regul; 2015 Jan; 57():10-6. PubMed ID: 25482988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
    Wang X; Ding J; Meng LH
    Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
    Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
    Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PI3K-AKT pathway for cancer therapy.
    Lu Y; Wang H; Mills GB
    Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in subunits of PI3K class I in cancer.
    Cui W; Cai Y; Zhou X
    Pathology; 2014 Apr; 46(3):169-76. PubMed ID: 24614719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/Akt signalling pathway and cancer.
    Fresno Vara JA; Casado E; de Castro J; Cejas P; Belda-Iniesta C; González-Barón M
    Cancer Treat Rev; 2004 Apr; 30(2):193-204. PubMed ID: 15023437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
    Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M
    Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
    Wolin EM
    Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt as a target for cancer therapy: more is not always better (lessons from studies in mice).
    Wang Q; Chen X; Hay N
    Br J Cancer; 2017 Jul; 117(2):159-163. PubMed ID: 28557977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.
    Houédé N; Pourquier P
    Pharmacol Ther; 2015 Jan; 145():1-18. PubMed ID: 24929024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.